UNC GI Cancer SPORE's unique goals emphasize multidisciplinary translational research that spans and links the population, clinical, and basic sciences. To decrease the burden of colorectal cancer on the patient population at large we will: (1) determine the clinical importance of new and existing targets on the colorectal cancer population (2) define the relationship of these molecular abnormalities to racial disparities (3) evaluate how best to manipulate these molecular targets for therapy, and (4) verify the target manipulation and effect in a group of colorectal cancer patients. To decrease colorectal cancer mortality a better understanding of the relationship of laboratory discoveries in signaling, oncogenesis and other molecular changes to the clinical setting is needed. We have developed projects that will allow us to accomplish these goals through the strong multi-disciplinary collaboration that already exists between clinical, laboratory and population-based scientists in the UNC Lineberger Comprehensive Cancer Center. The UNC GI Cancer SPORE's five projects and their translational objectives are: Project 1: Prognostic and Predictive Factors in Outcomes of Patients with Colorectal Cancer: A Population-Based Study. Determine which patient, treatment and molecular characteristics of colon cancer patients and their tumors will be predictive of prognosis, response to therapy and survival. Project 2: Molecular Changes in the NF-KappaB Pathway in Response to Chemoradiation Therapy in Rectal Cancer. Define in a clinical trial the NF-KappaB-related molecular responses of tumors and normal tissue during treatment compared to pre-treatment, the correlation of these responses with clinical outcome and the ability of proteasome inhibitors to modify this response to therapy. Using a variety of experimental models, determine if more specific approaches to NFkappaB inhibition will improve current regimens of colorectal cancer therapy. Project 3: Investigation of ERBB signaling in Colorectal Cancers during Liver Metastasis. To characterize, using patients with liver metastasis of colorectal cancer as a model, ERBB receptor activation, downstream signaling patterns and alterations in mRNA expression profiles of patients treated with a small molecule, dual kinase inhibitor in order to identify markers of response to ERBB directed therapy, to define reasons for treatment failure, and to correlate patient responses with the mouse model results. Project 4: Targeting the RAS>ERK Pathway for Colorectal Cancer Treatment. Determine whether a prospective group of patients with colorectal carcinomas that harbor mutated Ras show gene expression profiles that will predict their sensitivity to anti-Ras and anti-Raf or anti-MEK therapeutic strategies and to define the mechanisms for response or resistance. Project 5: Determination of the Role of Fucosyltransferases in Colorectal Cancer Initiation and Progression. To identify mutations and differential expression of human fucosyltransferases associated with the development of colorectal carcinoma, determine their potential interactions with NSAID use, apoptosis, diet and other genotypes, using samples from population-based databases. Core Resources in Administration, Genomics, Biostatistics and Bioinformatics, and Tissue Procurement and Analysis will enhance the specialized research of the SPORE. Career and Developmental Research Programs are also included.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA106991-03
Application #
7122855
Study Section
Special Emphasis Panel (ZCA1-GRB-V (J1))
Program Officer
Agarwal, Rajeev K
Project Start
2004-08-09
Project End
2009-07-31
Budget Start
2006-08-01
Budget End
2007-07-31
Support Year
3
Fiscal Year
2006
Total Cost
$2,213,973
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Asher, Gary N; Xie, Ying; Moaddel, Ruin et al. (2017) Randomized Pharmacokinetic Crossover Study Comparing 2 Curcumin Preparations in Plasma and Rectal Tissue of Healthy Human Volunteers. J Clin Pharmacol 57:185-193
Gao, Xingming; Zhu, Mengyuan; Fan, Haiying et al. (2015) A fluorescent bisboronic acid compound that selectively labels cells expressing oligosaccharide Lewis X. Bioorg Med Chem Lett 25:2501-4
Keku, Temitope O; Dulal, Santosh; Deveaux, April et al. (2015) The gastrointestinal microbiota and colorectal cancer. Am J Physiol Gastrointest Liver Physiol 308:G351-63
Lin, Ja-An; Zhu, Hongtu; Mihye, Ahn et al. (2014) Functional-mixed effects models for candidate genetic mapping in imaging genetic studies. Genet Epidemiol 38:680-91
Nugent, Julia L; McCoy, Amber N; Addamo, Cassandra J et al. (2014) Altered tissue metabolites correlate with microbial dysbiosis in colorectal adenomas. J Proteome Res 13:1921-9
Zhu, Hongtu; Ibrahim, Joseph G; Tang, Niansheng (2014) Bayesian Sensitivity Analysis of Statistical Models with Missing Data. Stat Sin 24:871-896
Nikolaishvilli-Feinberg, Nana; Cohen, Stephanie M; Midkiff, Bentley et al. (2014) Development of DNA damage response signaling biomarkers using automated, quantitative image analysis. J Histochem Cytochem 62:185-96
Wang, Hansong; Burnett, Terrilea; Kono, Suminori et al. (2014) Trans-ethnic genome-wide association study of colorectal cancer identifies a new susceptibility locus in VTI1A. Nat Commun 5:4613
McCoy, Amber N; Araújo-Pérez, Félix; Azcárate-Peril, Andrea et al. (2013) Fusobacterium is associated with colorectal adenomas. PLoS One 8:e53653
Kang, Melissa; Edmundson, Patrick; Araujo-Perez, Felix et al. (2013) Association of plasma endotoxin, inflammatory cytokines and risk of colorectal adenomas. BMC Cancer 13:91

Showing the most recent 10 out of 84 publications